IL240166A0 - spiro-lactam modulators of the NMDA receptor and their uses - Google Patents

spiro-lactam modulators of the NMDA receptor and their uses

Info

Publication number
IL240166A0
IL240166A0 IL240166A IL24016615A IL240166A0 IL 240166 A0 IL240166 A0 IL 240166A0 IL 240166 A IL240166 A IL 240166A IL 24016615 A IL24016615 A IL 24016615A IL 240166 A0 IL240166 A0 IL 240166A0
Authority
IL
Israel
Prior art keywords
spiro
nmda receptor
receptor modulators
lactam nmda
lactam
Prior art date
Application number
IL240166A
Other languages
English (en)
Hebrew (he)
Original Assignee
Naurex Inc
John A Lowe Iii
Amin Khan M
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50071822&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL240166(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Naurex Inc, John A Lowe Iii, Amin Khan M filed Critical Naurex Inc
Publication of IL240166A0 publication Critical patent/IL240166A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
IL240166A 2013-01-29 2015-07-27 spiro-lactam modulators of the NMDA receptor and their uses IL240166A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361757934P 2013-01-29 2013-01-29
PCT/US2014/013623 WO2014120786A1 (en) 2013-01-29 2014-01-29 Spiro-lactam nmda receptor modulators and uses thereof

Publications (1)

Publication Number Publication Date
IL240166A0 true IL240166A0 (en) 2015-09-24

Family

ID=50071822

Family Applications (1)

Application Number Title Priority Date Filing Date
IL240166A IL240166A0 (en) 2013-01-29 2015-07-27 spiro-lactam modulators of the NMDA receptor and their uses

Country Status (16)

Country Link
US (2) US9758525B2 (OSRAM)
EP (1) EP2951184A1 (OSRAM)
JP (1) JP6419087B2 (OSRAM)
KR (1) KR20150110787A (OSRAM)
CN (1) CN105229010A (OSRAM)
AU (1) AU2014212487C1 (OSRAM)
BR (1) BR112015018092A2 (OSRAM)
CA (1) CA2898863A1 (OSRAM)
CL (1) CL2015002123A1 (OSRAM)
EA (1) EA031905B1 (OSRAM)
IL (1) IL240166A0 (OSRAM)
MX (1) MX2015009773A (OSRAM)
PE (1) PE20151437A1 (OSRAM)
PH (1) PH12015501595A1 (OSRAM)
SG (1) SG11201505934XA (OSRAM)
WO (1) WO2014120786A1 (OSRAM)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011003015A (es) 2008-09-18 2011-11-18 Univ Northwestern Moduladores del receptor de n-metil-d-aspartato, y usos de los mismos.
HRP20230747T1 (hr) 2011-09-08 2024-01-05 Sage Therapeutics, Inc. Neuroaktivni steroidi, pripravci i njihova uporaba
EP2951186B1 (en) 2013-01-29 2018-07-25 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
US9708335B2 (en) 2013-01-29 2017-07-18 Apytinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
JP6531042B2 (ja) 2013-01-29 2019-06-12 アプティニックス インコーポレイテッド スピロラクタム系ｎｍｄａ受容体モジュレーターおよびその使用
EP2951184A1 (en) 2013-01-29 2015-12-09 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
PT3514158T (pt) 2013-01-29 2023-01-13 Aptinyx Inc Moduladores espirolactamas de um recetor nmda e as suas utilizações
CN105246486B (zh) 2013-03-13 2020-11-03 萨奇治疗股份有限公司 神经活性甾类化合物
JP6628745B2 (ja) 2014-06-18 2020-01-15 セージ セラピューティクス， インコーポレイテッド オキシステロールおよびその使用方法
IL292465B2 (en) * 2014-10-07 2025-06-01 Sage Therapeutics Inc Neuroactive compounds and methods of use thereof
CN104326943A (zh) * 2014-11-04 2015-02-04 崇州合瑞科技有限公司 一种制备Boc-L-丝氨酸的方法
CN104326960A (zh) * 2014-11-04 2015-02-04 崇州合瑞科技有限公司 一种制备Boc-L-脯氨酸的方法
ES2865258T3 (es) 2015-07-06 2021-10-15 Sage Therapeutics Inc Oxiesteroles y procedimientos de uso de los mismos
EP3319610A4 (en) 2015-07-06 2019-03-06 Sage Therapeutics, Inc. OXYSTEROLS AND METHOD OF USE THEREOF
KR20240166589A (ko) 2015-07-06 2024-11-26 세이지 테라퓨틱스, 인크. 옥시스테롤 및 그의 사용 방법
EP3411369A1 (en) * 2016-02-01 2018-12-12 Lupin Limited Process for the preparation of ledipasvir and intermediates thereof
MA44526A (fr) 2016-04-01 2021-06-02 Sage Therapeutics Inc Oxystérols et leurs méthodes d'utilisation
US10752653B2 (en) 2016-05-06 2020-08-25 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
CN105924402A (zh) * 2016-05-06 2016-09-07 蚌埠中实化学技术有限公司 一种2-胺基甲基嘧啶盐酸盐的制备方法
JP6590226B2 (ja) * 2016-05-11 2019-10-16 株式会社シード探索研究所 オキサアジリジン化合物およびその製造方法
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
EA201892657A1 (ru) * 2016-05-19 2019-05-31 Аптиникс Инк. Спиролактамовые модуляторы nmda-рецептора и их применение
EP3919502A1 (en) 2016-07-07 2021-12-08 Sage Therapeutics, Inc. 11-substituted 24-hydroxysterols for use in the treatment of nmda related conditions
PE20190503A1 (es) 2016-08-01 2019-04-10 Aptinyx Inc Moduladores del receptor nmda espiro-lactam y uso de los mismos
WO2018026798A1 (en) 2016-08-01 2018-02-08 Aptinyx Inc. Spiro-lactam nmda modulators and methods of using same
AU2017306136B2 (en) 2016-08-01 2021-10-21 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
CN109661398B (zh) * 2016-08-01 2022-07-05 阿普廷伊克斯股份有限公司 螺-内酰胺和二-螺-内酰胺nmda受体调节剂及其用途
CA3031539C (en) 2016-08-01 2023-11-28 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
MA46351A (fr) 2016-09-30 2021-06-02 Sage Therapeutics Inc Oxystérols substitués en c7 et procédés en tant que modulateurs nmda
EP4105223B1 (en) 2016-10-18 2025-04-30 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
RU2019115113A (ru) 2016-10-18 2020-11-24 Сейдж Терапьютикс, Инк. Оксистеролы и способы их применения
CN107602436A (zh) * 2017-09-29 2018-01-19 新发药业有限公司 一种n‑取代‑l‑焦谷氨酸酯的绿色制备方法
BR112020015710A2 (pt) 2018-01-31 2020-12-08 Aptinyx Inc. Moduladores de espiro-lactamas de receptores nmda e usos dos mesmos
WO2019152685A1 (en) * 2018-01-31 2019-08-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and methods of using same
US20210047324A1 (en) * 2018-01-31 2021-02-18 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
WO2019152696A1 (en) * 2018-01-31 2019-08-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
EP3986400B1 (en) * 2019-06-24 2024-08-21 Naurex Inc. Processes and intermediates for producing diazaspiro lactam compounds
MA56550A (fr) * 2019-06-24 2022-04-27 Naurex Inc Formes solides de tert-butyl (s)-2-((2s,3r)-1-amino-3-hydroxy-1-oxobu tan-2-yl)-1-oxo -2, 5-diazaspiro[3,4]octane-5-carboxylate et leurs procédés de préparation
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1305177C (en) 1987-06-30 1992-07-14 Yasufumi Ohfune Carboxycyclopropylglycine and process for producing the same
US4904681A (en) 1987-12-01 1990-02-27 G. D. Searle & Co. D-cycloserine and its prodrugs as cognitive enhancers
EP0360390A1 (en) 1988-07-25 1990-03-28 Glaxo Group Limited Spirolactam derivatives
US5061721A (en) 1989-03-15 1991-10-29 G. D. Searle & Co. Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US5086072A (en) 1990-06-18 1992-02-04 The United States Of America As Represented By The Department Of Health And Human Services Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
US5350769A (en) 1990-10-30 1994-09-27 Ss Pharmaceutical Co., Ltd. Antiinflammatory gel preparation
US5168103A (en) 1991-01-22 1992-12-01 American Home Products Corporation [[2-(amino-3,4-dioxo-1-cyclobuten-1-yl) amino]alkyl]-acid derivatives
FR2692268B1 (fr) 1992-06-15 1994-08-19 Rhone Poulenc Rorer Sa Nouveaux polypeptides ayant une activité de récepteur NMDA, acides nucléiques codant pour ces polypeptides et utilisations.
SE9301667D0 (sv) 1993-05-14 1993-05-14 Kabi Pharmacia Ab New use
US5523323A (en) 1993-09-14 1996-06-04 Maccecchini; Maria-Luisa Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence
US5605911A (en) 1995-01-31 1997-02-25 Washington University Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH)
US6335358B1 (en) 1995-04-12 2002-01-01 President And Fellows Of Harvard College Lactacystin analogs
US5741778A (en) 1996-03-19 1998-04-21 Amgen Inc. Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product
US5763393A (en) 1996-05-17 1998-06-09 Neurotherapeutics L.P. Neuroactive peptides
CA2252417A1 (en) 1996-06-07 1997-12-11 Zeneca Limited Peptide derivatives
WO1998005782A1 (en) 1996-08-02 1998-02-12 Zymogenetics, Inc. Testis-specific insulin homolog polypeptides
US5902815A (en) 1996-09-03 1999-05-11 Washington University Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction
JP3955345B2 (ja) 1996-09-27 2007-08-08 サントリー株式会社 新規アミノ酸ダイジハーベイン
WO1999024584A1 (en) 1997-11-12 1999-05-20 Neurotherapeutics Methods for the detection and treatment of disease using a glycosyltransferase
US5952389A (en) 1998-01-13 1999-09-14 Synchroneuron Methods of treating tardive dyskinesia and other movement disorders
US6007841A (en) 1998-03-13 1999-12-28 Algos Pharmaceutical Corporation Analgesic composition and method for treating pain
US6274314B1 (en) 1998-04-02 2001-08-14 Nyxis Neurotherapies, Inc. Diagnostic assay for the modified nucleosides pseudouridine, 7-methyladenosine, or 1-methyladenosine
US6197820B1 (en) 1998-04-06 2001-03-06 Uab Research Foundation Use of phenylglycine derivatives to decrease neuronal death caused by brain tumors and brain lesions
US6025471A (en) 1998-06-03 2000-02-15 Deghenghi; Romano Diazaspiro, azepino and azabicyclo therapeutic peptides
AU1724000A (en) 1998-11-12 2000-05-29 Nyxis, Inc. Diagnostic assay for cancer
US20030064921A1 (en) 1999-10-27 2003-04-03 The Regents Of The University Of California Methods and compounds for modulating melanocortin receptor ligand binding and activity
WO2001036685A2 (en) 1999-11-17 2001-05-25 Nyxis Neurotherapies, Inc. Differential gene expression in cancer
EP1255854A2 (en) 2000-02-01 2002-11-13 Agy Therapeutics, Inc. Interaction of nmda receptor with protein tyrosine phosphatase
AU2001268467A1 (en) 2000-06-14 2001-12-24 Nyxis Neurotherapies, Inc. Identification of genes and compounds for treatment of cancer
WO2001098367A2 (en) 2000-06-22 2001-12-27 Nyxis Neurotherapies, Inc. Neuroactive peptides for treatment of hypoxia and related conditions
GB0018272D0 (en) 2000-07-25 2000-09-13 Vernalis Research Limited Chemical compounds IV
EP1186303A3 (en) 2000-09-06 2003-12-10 Pfizer Products Inc. Pharmaceutical combinations, for the treatment of stroke and traumatic brain injury, containing a neutrophil inhibiting factor and an selective NMDA-NR2B receptor antagonist
IL145209A0 (en) 2000-09-06 2002-06-30 Pfizer Prod Inc Pharmaceutical combinations for the treatment of stroke and traumatic brain injury
UA73619C2 (en) 2000-12-13 2005-08-15 Pfizer Prod Inc Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment
WO2002047535A2 (en) 2000-12-14 2002-06-20 Nyxis Neurotherapies, Inc. High throughput assay to detect inhibitors of the map kinase pathway
US20030065138A1 (en) 2001-03-07 2003-04-03 University Of Utah Research Foundation Linear gamma-carboxyglutamate rich conotoxins
WO2002072609A2 (en) 2001-03-12 2002-09-19 Nyxis Neurotherapies, Inc Neuroactive peptides for prevention and/or treatment of hypoxia and neuropathic pain
WO2003010540A1 (en) 2001-07-25 2003-02-06 Nyxis Neurotherapies, Inc. Method of identifying nmda-related agent
BR0312414A (pt) 2002-07-05 2005-05-10 Targacept Inc Compostos de n-aril diazaespirociclico e métodos para a preparação e uso dos mesmos
US7273889B2 (en) 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
US7544478B2 (en) 2003-08-08 2009-06-09 The Burnham Institute Method for screening for compounds that modulate P16 mediated regulation of NMDA receptors
US7662856B2 (en) 2003-08-29 2010-02-16 The University Of Houston System Compositions having antimycrobial activity including a hydroxamate or a hydroxamate and a hydroxlyamine
GB0323204D0 (en) 2003-10-03 2003-11-05 Novartis Ag Organic compounds
US20050096311A1 (en) 2003-10-30 2005-05-05 Cns Response Compositions and methods for treatment of nervous system disorders
US20060063707A1 (en) 2004-09-17 2006-03-23 Lifelike Biomatic, Inc. Compositions for enhancing memory and methods therefor
DK1868614T3 (da) 2005-03-24 2012-11-12 Univ Emory Dosisregime til behandling af en traumatisk hjerneskade med progesteron
CA2620361C (en) 2005-08-26 2014-10-14 Wisconsin Alumni Research Foundation Poly-beta-peptides from functionalized beta-lactam monomers and antibacterial compositions containing same
US20070208001A1 (en) 2006-03-03 2007-09-06 Jincong Zhuo Modulators of 11- beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
CA2663502A1 (en) 2006-09-15 2008-03-20 Schering Corporation Azetidinone derivatives and methods of use thereof
JP2008188285A (ja) 2007-02-06 2008-08-21 Bridgestone Corp バックパッド及び車両用シート
CN101066945B (zh) 2007-05-25 2010-05-19 中国科学院上海有机化学研究所 一种合成3-位取代内酰胺类化合物的方法
CN101125817B (zh) 2007-08-03 2011-09-14 中国科学院上海有机化学研究所 一种合成高对映选择性醛基取代小环胺类化合物和光学活性3-位取代内酰胺类化合物的方法
WO2009039390A2 (en) 2007-09-20 2009-03-26 Naurex Inc. The development of glycobiology-based therapeutics for the treatment of brain tumors
AU2009217278B2 (en) 2008-02-20 2015-08-20 The Children's Hospital Of Philadelphia Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatment of autism
CN102112442B (zh) 2008-08-07 2014-12-10 弗·哈夫曼-拉罗切有限公司 制备大环的方法
MX2011003015A (es) 2008-09-18 2011-11-18 Univ Northwestern Moduladores del receptor de n-metil-d-aspartato, y usos de los mismos.
MX2011002994A (es) * 2008-09-19 2011-05-30 Concert Pharmaceuticals Inc Compuestos de morfinan.
WO2010065709A2 (en) 2008-12-03 2010-06-10 Amin Khan Hydroxamic acid derivatives, preparation and therapeutic uses thereof
DE102009001460B4 (de) 2009-03-11 2010-12-02 Zf Friedrichshafen Ag Ölbehälter
US20120178695A1 (en) 2009-07-02 2012-07-12 Joseph Moskal Methods of treating neuropathic pain
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
HRP20140784T1 (hr) 2009-10-05 2014-10-10 Northwestern University Glyx-13 za uporabu u postupku tretiranja refraktornih depresija
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
SG10201811584RA (en) 2010-02-11 2019-01-30 Univ Northwestern Secondary Structure Stabilized NMDA Receptor Modulators And Uses Thereof
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
CN108283712A (zh) 2011-04-27 2018-07-17 西北大学 治疗阿尔茨海默氏症、亨廷顿氏症、孤独症和其他障碍的方法
JP6388536B2 (ja) 2011-06-27 2018-09-12 コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． 超音波振動子アセンブリ及びその製造方法
JP6531042B2 (ja) 2013-01-29 2019-06-12 アプティニックス インコーポレイテッド スピロラクタム系ｎｍｄａ受容体モジュレーターおよびその使用
PT3514158T (pt) 2013-01-29 2023-01-13 Aptinyx Inc Moduladores espirolactamas de um recetor nmda e as suas utilizações
US9708335B2 (en) 2013-01-29 2017-07-18 Apytinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
EP2951186B1 (en) 2013-01-29 2018-07-25 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
EP2951184A1 (en) 2013-01-29 2015-12-09 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof

Also Published As

Publication number Publication date
PE20151437A1 (es) 2015-10-10
CL2015002123A1 (es) 2015-12-04
JP2016506960A (ja) 2016-03-07
US9758525B2 (en) 2017-09-12
WO2014120786A1 (en) 2014-08-07
US10273239B2 (en) 2019-04-30
EP2951184A1 (en) 2015-12-09
MX2015009773A (es) 2016-08-05
CA2898863A1 (en) 2014-08-07
AU2014212487B2 (en) 2018-04-19
EA031905B1 (ru) 2019-03-29
AU2014212487C1 (en) 2018-10-25
SG11201505934XA (en) 2015-09-29
BR112015018092A2 (pt) 2017-07-18
US20180179217A1 (en) 2018-06-28
KR20150110787A (ko) 2015-10-02
PH12015501595B1 (en) 2015-10-19
AU2014212487A1 (en) 2015-07-30
EA201591403A1 (ru) 2017-05-31
JP6419087B2 (ja) 2018-11-07
CN105229010A (zh) 2016-01-06
PH12015501595A1 (en) 2015-10-19
US20150368253A1 (en) 2015-12-24

Similar Documents

Publication Publication Date Title
IL281240B (en) Androgen receptor modulator and uses thereof
IL240166A0 (en) spiro-lactam modulators of the NMDA receptor and their uses
IL240164A0 (en) spiro-lactam modulators of the NMDA receptor and their uses
IL240163B (en) spiro-lactam modulators of the NMDA receptor and their uses
IL240162B (en) spiro-lactam modulators of the NMDA receptor and their uses
IL240165A0 (en) spiro-lactam modulators of the NMDA receptor and their uses
IL242611B (en) Estrogen receptor modulator and uses thereof
IL245733A0 (en) aplnr modulators and their uses
IL240929A0 (en) 7- Converted azabicycles and their use as orexin receptor modulators
IL254921B (en) Pyridopyrimidinones and their uses as nmda receptor modulators
SI3386591T1 (sl) Heteroaromatski NMDA receptorski modulatorji in njihove uporabe
IL245302A0 (en) nmda receptor modulators and their prodrugs, salts and uses
GB201312727D0 (en) Modulators
EP3013851A4 (en) MODULATORS OF BRADYKININ RECEPTORS AND THEIR USE
GB201318298D0 (en) Modulators
GB201317988D0 (en) Modulators
GB201304473D0 (en) Modulators